Immunological Aspects of Hodgkin's Disease
An overriding question is whether in Hodgkin's disease, as with other neoplasms (Baldwin 1971 , Hellstrom & Hellstrom 1969 , 1970 , there are specific cellular and humoral immune responses to tumour-associated antigens. A significant increase in Epstein-Barr (EB) virus antibodies has been observed using immunofluorescence methods in Hodgkin"s patients, particularly those with mixed cellularity and lymphocyte depletion (Johansson et al. 1970 , Levine et al. 1971 , indicating the presence of EB-associated intracellular and cell membrane antigens. These studies add to the already established disease-associated EBvirus antibody patterns in Burkitt's lymphoma and nasopharyngeal carcinoma (Klein 1971 ) and draw attention to the possible relation between infectious mononucleosis and Hodgkin's disease (Kaplan 1971) . Immunofluorescence studies with heterologous antisera against perisplenic lymph nodes and splenic tumour nodules from Hodgkin's patients have also detected cross-reacting abnormal antigens not present in normal splenic tissue, but as yet the specificity of these antigens remains unexplored (Order et al. 1971 ).
Impairment of cell-mediated immunity in
Hodgkin's patients has been frequently demonstrated by showing depressed hypersensitivity responses to agents such as dinitrochlorobenzene (DNCB) and bacterial antigens (Brown et al. 1967 , Kaplan 1970 ). These observations have been interpreted as showing that Hodgkin's disease is characterized by a progressive loss of thymus-derived (T cell) lymphocytes which are functionally involved in immunosurveillance mechanisms (Good et al. 1971) . More definitive studies of the cellular immune defect in early untreated patients are needed to reconcile the contradictory findings of Brown et al. (1967) and Kaplan (1970) , but recent unpublished studies by Kaplan (1971) confirm that defective responses to DNCB hypersensitization occur at early stages.
These findings focus attention on the mechanism of the aberration and its progressive increase with advanced disease. The possibility must also be considered that humoral and cell-mediated factors act antagonistically, since there is evidence to support this concept from studies of a variety of both experimental and human solid tumours (Baldwin 1971 , Hellstrom & Hellstrom 1970 , Hellstrom et al. 1971 ).
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Results of Treatment
Thirty years ago Hodgkin's disease and allied lymph node disorders were accepted as inevitably fatal. Investigations were limited usually to a simple chest X-ray and blood count and early treatment was either avoided, until troublesome symptoms developed, or limited to the irradiation of small localized groups of superficial lymph nodes. This approach was justifiable if one accepted that these disorders were inevitably fatal. Clearly no doctor would wish to submit his patient to unnecessary and possibly unpleasant investigations when no cure was possible. Modern concepts have completely altered this pessimistic approach. The previous speakers have indicated that radical investigation and energetic treatment must now be accepted in the management and cure of 'incurable' Hodgkin's disease. Neither radical investigation nor energetic treatment are complication-free, and it is necessary to examine these new vigorous approaches to make sure that they are justifiable. Is Hodgkin's Disease Curable? Dr W B Dawson (see above, p 1109) has indicated that recent publications refer to patients surviving for many years after radiotherapy. In the Middlesex Hospital series (Jelliffe & Thomson 1955) there were some patients who at that time had survived for twenty years. The word 'cure' was not used in this original publication in 1955 because in those days Hodgkin's disease was still regarded as incurable and it was considered bad form to use this word when referring
